上海 + 86.21.2201.8034

Lillian He's practice focuses on dispute resolution, investigation and compliance matters, including cross-border litigation, anticorruption investigations, data privacy and data protection, and anti-money laundering and trade compliance.

Lillian has recently assisted several U.S. public companies in responding to government inquiries into violations of the Foreign Corrupt Practices Act (FCPA) in China and assisted in global compliance reviews for multinationals with significant operations in China and Asia. She also represented Chinese clients in U.S. litigations, arbitrations, and investigations and provided advice to Chinese clients on economic sanctions programs administered by the U.S. Department of Treasury's Office of Foreign Assets Control (OFAC).

In addition, Lillian has experience advising multinational companies on data privacy, cybersecurity, and data breach incident response matters. She has represented clients in various sectors in China, such as retail, health care, automotive manufacturing, chemical, information, and technology.


  • Major U.S. software company conducts enhanced end user due diligence requirementsJones Day assisted a major U.S. software company with enhanced end user due diligence requirements in compliance with a procedure from the Bureau of Industry and Security (BIS).
  • P&G sells Vidal Sassoon brand in Greater ChinaJones Day advised The Procter & Gamble Company in the sale of its Vidal Sassoon hair care consumer products business to Henkel AG & Co. KGaA.
  • WEG acquires industrial electric motors and generators business from Regal Rexnord CorporationJones Day advised WEG S.A. in the $400 million acquisition of the industrial electric motors and generators business of Regal Rexnord Corporation.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Helios Technologies completes acquisition of assets of JoyonwayJones Day advised Helios Technologies, Inc. in the acquisition of assets related to the electronic control systems and parts business of Shenzhen Joyonway Electronics & Technology Co., Ltd and its related entities (collectively “Joyonway”).
  • Chinese financial institution secures early dismissal of breach of contract case filed in New York Supreme CourtJones Day helped a Chinese financial institution secure an early dismissal of a breach of contract case that plaintiffs filed in New York Supreme Court.
  • Telecommunications joint venture defends against enforcement measures that were brought following cross-border arbitrationJones Day represented a telecommunications joint venture in defending against efforts to enforce a partial arbitral award against it in Chinese courts.
  • U.S. fashion retailer reviews internal reports of alleged kickbacks and alleged misconductJones Day reviewed internal reports of alleged kickbacks and alleged misconduct raised by a client’s supplier, and helped the client carry out remedial measures following review.
  • Life sciences company resolves FCPA issues with DOJ and SECJones Day represented a publicly traded life sciences company in an internal investigation and resulting self-disclosure to the U.S. Department of Justice ("DOJ") and U.S. Securities and Exchange Commission ("SEC") involving alleged Foreign Corrupt Practices Act ("FCPA") violations arising out of the company's China operations.
  • Chinese financial institution responds to subpoena for records in major U.S. investigationJones Day represented a Chinese financial institution in a matter relating to a significant U.S. government investigation.
  • Global industrial manufacturing company revises compliance programJones Day assisted a global industrial manufacturing company in revising its third-party compliance policies and controls.
  • Global services company investigates allegations of corruption in its China operationsJones Day assisted a global services company investigate allegations of corrupt payments in its China sales operations.
  • Shenglong Technologies reaches settlement against former broker in U.S. district courtJones Day represented Ningbo Superim Shenglong Technologies Co., Ltd. and its parent company, Yinyi Group Co., Ltd. in U.S. district court against Shenglong's former broker in a factory acquisition.
  • HNA settles trademark infringement action relating to musical workJones Day represented Hainan Airlines Holding Co., Ltd. ("HNA") in a trademark infringement action relating to the use of a musical work.
  • Public company discloses FCPA issues to DOJ and SECJones Day coordinated the internal investigation and resulting self-disclosure to the U.S. Department of Justice ("DOJ") and the U.S. Securities and Exchange Commission ("SEC") for a public company involved in industrial and manufacturing work regarding Foreign Corrupt Practices Act ("FCPA") issues arising out of the company’s China office.
  • Automotive parts company conducts internal investigationOn behalf of an automotive parts company, Jones Day conducted an internal investigation into allegations of misconduct, self-dealing, and bribery related to the client’s subsidiary and distributor.
  • Pharmaceutical company successfully defends charge of commercial briberyA pharmaceutical company represented by Jones Day (in conjunction with local counsel) successfully challenged a charge of commercial bribery by a local branch of the Shanghai Administration of Industry and Commerce (AIC).
  • Sherwin-Williams acquires Valspar for $11.3 billionJones Day advised The Sherwin-Williams Company in its $11.3 billion acquisition of The Valspar Corporation.
  • Public life sciences company conducts anti-corruption due diligence on multiple acquisition targets in ChinaJones Day counseled a public U.S. life sciences company with respect to anti-corruption due diligence on more than a dozen acquisition targets operating in China.
  • Publicly traded company conducts anti-corruption investigation of physician sponsorship payments in Asia PacificJones Day assisted a publicly traded company with an investigation of whistleblower allegations that physician sponsorship payments in Asia Pacific violated U.S. and local anti-corruption laws.